The abstract is read at the publisher; the summary is JClub's.
A single dose of the YF17D-vectored rabies vaccine candidate YF-RabG induced rabies virus-neutralizing antibody titres that exceeded the correlate of protection by several orders in mice, hamsters, and non-human primates.
- Why it matters: Pre-exposure rabies vaccination is limited by the need for multiple doses and repeated visits, so a single-dose approach with durable, functional immunity is needed.
- What they did: YF-RabG, a live-attenuated YF17D backbone stably expressing RabG, was tested in neonatal and immunocompromised mice and in non-human primates for humoral and cell-mediated responses, then challenged with lethal rabies in stringent mouse models.
- The result: Vaccination protected against lethal challenge, maintained seroprotective antibody levels for at least one year, and improved after boosting with a licensed rabies vaccine; the YF17D vector was also adapted to lyssavirus glycoproteins for protective candidates against Mokola, Lagos bat, and Lleida bat lyssaviruses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.